Piper Sandler sets USD 160.00 target for iRhythm stock

Published on 10/20/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler sets a USD 160.00 target on October 16, 2026. iRhythm stock costs EUR 101.50 on October 20, 2026, up 4.25 percent on Nasdaq.

Analyst coverage and trading

Piper Sandler began coverage with a USD 160.00 target on October 16, 2026.
Second-quarter revenue reached USD 224.17 million, up 20.1 percent year over year.
iRhythm stock costs EUR 101.50 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, with Nasdaq trading up 4.25 percent.
Third-quarter results are scheduled for November 5, 2026.

IRMD, US4500561067, Illustration mit AI erstellt.

iRhythm Technologies (ISIN US4500561067) drew a USD 160.00 price target when MarketScreener reported Piper Sandler's new Overweight rating on October 16, 2026. The target stands 40.04 percent above the Nasdaq price of USD 114.25 at 3:51 p.m. ET on October 20, 2026. After hours, the stock was trading at EUR 101.50 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, while Nasdaq trading was up 4.25 percent.

Revenue reached USD 224.17 million

The latest reported quarter gives the analyst view an operating anchor. According to iRhythm, revenue in the second quarter of 2026 reached USD 224.17 million, up 20.10 percent from USD 186.69 million in the second quarter of 2025. Gross margin rose to 72.80 percent from 71.20 percent, while adjusted EBITDA increased to USD 43.30 million from USD 15.70 million.

The quarter also marked a sharp improvement in adjusted profitability. Adjusted net income was USD 19.32 million in the second quarter of 2026, compared with an adjusted net loss of USD 10.22 million in the same quarter of 2025.

Stock remains near its yearly low

The Nasdaq quote places iRhythm at USD 114.25, versus a 52-week range of USD 100.70 to USD 212.00 as of October 20, 2026. The price therefore stood 43.16 percent below the yearly high and 13.45 percent above the yearly low. The market capitalization was USD 3.8 billion, with 379,512 shares traded by 3:51 p.m. ET.

Valuation and next reporting date

For comparison, DexCom traded at USD 85.71 on October 20, 2026, down 0.31 percent, with a price-to-earnings ratio of 33.86 and market capitalization of USD 32.3 billion. Insulet traded at USD 142.87, up 0.64 percent, with a price-to-earnings ratio of 26.70 and market capitalization of USD 9.9 billion.

MarketScreener lists November 5, 2026 as the date for iRhythm's third-quarter 2026 financial results. The USD 160.00 target from October 16, 2026 remains the clearest dated analyst reference in the current trading picture.

Price and analyst target

The euro quote and the Nasdaq price describe separate venues, but both place the stock well below Piper Sandler's USD 160.00 target. The next results date will provide the next formal test of the company's USD 880 million to USD 890 million full-year 2026 revenue outlook.

The further course of trading is shown by the continuously updated real-time quote of iRhythm stock.